MAGI3 and breast carcinoma: Collectively, these data demonstrate that the recurrent MAGI3pPA product and other breast cancer-associated MAGI3 truncations suppress the inhibitory interaction between full-length MAGI3 and YAP, thus providing a molecular link between their dominant-negative activity and their oncogenic nature.